FILTER

FILTERED INTERVIEW RESULTS

Massimo Scaccabarozzi

PRESIDENT, FARMINDUSTRIA
Farmindustria speaks to GBR about the importance of pharmaceuticals to the Italian economy and society.

Massimiliano Rocchi

SENIOR DIRECTOR ITALY AND GREECE, ACCORD HEALTHCARE ITALIA
Accord Healthcare Italia explains the challenges and opportunities for generics producers in Italy.

Luca Crippa

CEO & MANAGING DIRECTOR, IBSA FARMACEUTICI
Instituto Biochimico, with 2,000 global employees, is attempting to take generics to the next level and continue to expand around the world.

Franco Lori

CEO & FOUNDER, VIROSTATICS
Virostatics is a private drug discovery and development company focused on NCEs used in the treatment of cancers and viral diseases.

Cosimo Lenti

BUSINESS DIRECTOR, DIATHEVA
Diatheva promotes biotechnological innovation by providing high-value customized diagnostic kits and solutions.

Gilda D'Incerti

CEO AND FOUNDER, PQE GROUP
PQE Group explains its imperative to expand rapidly apace with the global life science industry.

Andrea Lodetti

CEO, BORMIOLI PHARMA
Bormioli Pharma discusses its plans to maintain its expansion.

Riccardo Palmisano

PRESIDENT, ASSOBIOTEC
Federchimica Assobiotec explains how the association is striving to help Italy’s biotech industry reach the scale that its’ potential offers.

Giovanni Sala

GENERAL MANAGER, MEDAC PHARMA
Medac Pharma explains how producers of original drugs struggle to gain a fair price in Italy.

Enrique Hausermann

PRESIDENT, EGUALIA
Egualia is the Italian association for generics, biosimilars and VMAs and comments on some of the challenges that its’ members face.

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

MACIG 2025 - Mining in Africa Country Investment Guide

It is said that mining is a patient industry. Current demand projections are not. Demand for minerals deemed ‘critical’ is set to increase almost fourfold by 2030, according to the UN. Demand for nickel, cobalt and lithium is predicted to double, triple and rise ten-fold, respectively, between 2022 and 2050. The world will need to mine more copper between 2018 and 2050 than it has mined throughout history. 2050 is also the deadline to curb emissions before reaching a point of ‘no return.’ The pace of mineral demand and the consequences of not meeting it force the industry to act fast and take more risks. Mining cannot afford to be a patient industry anymore. The scramble for supply drives miners back to geological credentials, and therefore to places like the African Central Copperbelt.

PARTNER EVENTS